New Approaches to the Treatment of Latent Tuberculosis

 

 Buy Article Permissions and Reprints

ABSTRACT

It is estimated that one third of the global population is infected with Mycobacterium tuberculosis. Treatment of M. tuberculosis infection is an important strategy for tuberculosis elimination, but the effectiveness of this strategy is limited by poor adherence to therapy, which is due at least in part to the long duration of treatment. A 9-month course of isoniazid is the currently preferred treatment regimen for M. tuberculosis infection, due to the extensive data regarding the effectiveness and tolerability of isoniazid, and limited data on the effectiveness and tolerability of alternative shorter-course regimens. This review covers all currently available regimens, including less established alternative treatment regimens (e.g., rifampin for 4 months and isoniazid + rifampin for 3 months), as well as regimens that are currently under investigation (e.g., isoniazid + rifapentine for 3 months). Potential future regimens and experimental approaches are also discussed.

REFERENCES

• 1 American Thoracic Society, Centers for Disease Control and Prevention . Targeted tuberculin testing and treatment of latent tuberculosis infection.  Am J Respir Crit Care Med. 2000;  161 S221-S247
  PubMedGoogle Scholar
• 2 Pediatric Tuberculosis Collaborative Group . Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents.  Pediatrics. 2004;  114 1175-1201
  CrossrefPubMedGoogle Scholar
• 3 Blumberg H M, Leonard Jr M K, Jasmer R M. Update on the treatment of tuberculosis and latent tuberculosis infection.  JAMA. 2005;  293 2776-2784
  CrossrefPubMedGoogle Scholar
• 4 Dye C, Scheele S, Dolin P, Pathania V, Raviglione M C. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country.  JAMA. 1999;  282 677-686
  CrossrefPubMedGoogle Scholar
• 5 Khan K, Wang J, Hu W, Bierman A, Li Y, Gardam M. Tuberculosis infection in the United States: national trends over three decades.  Am J Respir Crit Care Med. 2008;  177 455-460
  PubMedGoogle Scholar
• 6 Bennett D E, Courval J M, Onorato I et al.. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999–2000.  Am J Respir Crit Care Med. 2008;  177 348-355
  CrossrefPubMedGoogle Scholar
• 7 Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli.  Adv Tuberc Res. 1976;  19 1-63
  PubMedGoogle Scholar
• 8 Comstock G W, Livesay V T, Woolpert S F. The prognosis of a positive tuberculin reaction in childhood and adolescence.  Am J Epidemiol. 1974;  99 131-138
  PubMedGoogle Scholar
• 9 Horsburgh Jr C R. Priorities for the treatment of latent tuberculosis infection in the United States.  N Engl J Med. 2004;  350 2060-2067
  CrossrefPubMedGoogle Scholar
• 10 Tufariello J M, Chan J, Flynn J L. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection.  Lancet Infect Dis. 2003;  3 578-590
  PubMedGoogle Scholar
• 11 Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research.  Ann Intern Med. 2007;  146 340-354
  CrossrefPubMedGoogle Scholar
• 12 American Thoracic Society, Centers for Disease Control and Prevention . Diagnostic standards and classification of tuberculosis in adults and children.  Am J Respir Crit Care Med. 2000;  161 1376-1395
  PubMedGoogle Scholar
• 13 Centers for Disease Control and Prevention . Missed opportunities for prevention of tuberculosis among persons with HIV infection: selected locations, United States, 1996–1997.  MMWR Morb Mortal Wkly Rep. 2000;  49 685-687
  PubMedGoogle Scholar
• 14 Reichler M R, Reves R, Bur S et al.. Treatment of latent tuberculosis infection in contacts of new tuberculosis cases in the United States.  South Med J. 2002;  95 414-420
  PubMedGoogle Scholar
• 15 Sterling T R, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh C R. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada.  Am J Respir Crit Care Med. 2006;  173 927-931
  CrossrefPubMedGoogle Scholar
• 16 LoBue P A, Moser K S. Use of isoniazid for latent tuberculosis infection in a public health clinic.  Am J Respir Crit Care Med. 2003;  168 443-447
  CrossrefPubMedGoogle Scholar
• 17 Jereb J, Etkind S C, Joglar O T, Moore M, Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999.  Int J Tuberc Lung Dis. 2003;  7(12 Suppl 3) S384-S390
  PubMedGoogle Scholar
• 18 Horsburgh R, Goldberg S, Bethel J et al.. Low latent tuberculosis infection treatment completion with 9 month INH regimen [abstract].  Am J Respir Crit Care Med. 2007;  175 A24
  PubMedGoogle Scholar
• 19 Manabe Y C, Bishai W R. Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting.  Nat Med. 2000;  6 1327-1329
  PubMedGoogle Scholar
• 20 International Union Against Tuberculosis . Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial.  Bulletin of the World Health Organization. 1982;  60 555-564
  PubMedGoogle Scholar
• 21 Comstock G W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?.  Int J Tuberc Lung Dis. 1999;  3 847-850
  PubMedGoogle Scholar
• 22 Comstock G W, Hammes L M, Pio A. Isoniazid prophylaxis in Alaskan boarding schools: a comparison of two doses.  Am Rev Respir Dis. 1969;  100 773-779
  PubMedGoogle Scholar
• 23 Mount F W, Ferebee S H. Preventive effects of isoniazid in the treatment of primary tuberculosis in children.  N Engl J Med. 1961;  265 713-721
  PubMedGoogle Scholar
• 24 Bucher H C, Griffith L E, Guyatt G H et al.. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials.  AIDS. 1999;  13 501-507
  CrossrefPubMedGoogle Scholar
• 25 Pape J W, Jean S S, Ho J L, Hafner A, Johnson W D. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection.  Lancet. 1993;  342 268-272
  CrossrefPubMedGoogle Scholar
• 26 Moreno S, Miralles P, Diaz M D et al.. Isoniazid preventive therapy in human immunodeficiency virus-infected persons: long-term effect on development of tuberculosis and survival.  Arch Intern Med. 1997;  157 1729-1734
  CrossrefPubMedGoogle Scholar
• 27 de Pinho A M, Santoro-Lopes G, Harrison L H, Schechter M. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil.  AIDS. 2001;  15 2129-2135
  CrossrefPubMedGoogle Scholar
• 28 Whalen C C, Johnson J L, Okwera A et al.. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus.  N Engl J Med. 1997;  337 801-808
  CrossrefPubMedGoogle Scholar
• 29 Quigley M A, Mwinga A, Hosp M et al.. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults.  AIDS. 2001;  15 215-222
  CrossrefPubMedGoogle Scholar
• 30 Gordin F M, Matts J P, Miller C et al.. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis.  N Engl J Med. 1997;  337 315-320
  CrossrefPubMedGoogle Scholar
• 31 Ferebee S H, Mount F W. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts.  Am Rev Respir Dis. 1962;  85 490-521
  PubMedGoogle Scholar
• 32 Scharer L, Smith J P. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid.  Ann Intern Med. 1969;  71 1113-1120
  PubMedGoogle Scholar
• 33 Byrd C B, Nelson R, Elliott R C. Isoniazid toxicity: a prospective study in secondary chemoprophylaxis.  JAMA. 1972;  220 1471-1473
  CrossrefPubMedGoogle Scholar
• 34 Bailey W C, Taylor S L, Dascomb H E, Greenberg H B, Ziskind M M. Disturbed hepatic function during isoniazid prophylaxis.  Am Rev Respir Dis. 1973;  107 523-529
  PubMedGoogle Scholar
• 35 Byrd R B, Horn B R, Griggs G A, Solomon D A. Isoniazid chemoprophylaxis: association with detection and incidence of liver toxicity.  Arch Intern Med. 1977;  137 1130-1133
  CrossrefPubMedGoogle Scholar
• 36 Byrd R B, Horn B R, Solomon D A, Griggs G A. Toxic effects of isoniazid in tuberculosis chemoprophylaxis: role of biochemical monitoring in 1,000 patients.  JAMA. 1979;  241 1239-1241
  CrossrefPubMedGoogle Scholar
• 37 Stuart R L, Wilson J, Grayson M L. Isoniazid toxicity in health care workers.  Clin Infect Dis. 1999;  28 895-897
  CrossrefPubMedGoogle Scholar
• 38 Bailey W C, Weill H, DeRouen T A, Ziskind M M, Jackson H A, Greenberg H B. The effect of isoniazid on transaminase levels.  Ann Intern Med. 1974;  81 200-202
  PubMedGoogle Scholar
• 39 Mitchell J R, Long M W, Thorgeirsson U P, Jollow D J. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy.  Chest. 1975;  68 181-190
  CrossrefPubMedGoogle Scholar
• 40 Litt I F, Cohen M I, McNamara H. Isoniazid hepatitis in adolescents.  J Pediatr. 1976;  89 133-135
  PubMedGoogle Scholar
• 41 Dickinson D S, Bailey W C, Hirschowitz B I, Soong S J, Eidus L, Hodgkin M M. Risk factors for isoniazid (INH)-induced liver dysfunction.  J Clin Gastroenterol. 1981;  3 271-279
  CrossrefPubMedGoogle Scholar
• 42 Kopanoff D E, Snider Jr D E, Caras G J. Isoniazid-related hepatitis: a U.S. Public Health Service Cooperative Surveillance Study.  Am Rev Respir Dis. 1978;  117 991-1001
  PubMedGoogle Scholar
• 43 Nolan C M, Goldberg S V, Buskin S E. Hepatoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.  JAMA. 1999;  281 1014-1018
  CrossrefPubMedGoogle Scholar
• 44 Dash L A, Comstock G W, Flynn J PG. Isoniazid preventive therapy.  Am Rev Respir Dis. 1980;  121 1039-1044
  PubMedGoogle Scholar
• 45 Snider Jr D E, Caras G J. Isoniazid-associated hepatitis deaths: a review of available information.  Am Rev Respir Dis. 1992;  145 494-497
  PubMedGoogle Scholar
• 46 Tuberculosis Chemotherapy Centre, Madras . The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis.  Bull WHO. 1963;  29 457-481
  PubMedGoogle Scholar
• 47 Snider Jr D E. Pyridoxine supplementation during isoniazid therapy.  Tubercle. 1980;  61 191-196
  CrossrefPubMedGoogle Scholar
• 48 Hawken M P, Meme H K, Elliott L C et al.. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial.  AIDS. 1997;  11 875-882
  CrossrefPubMedGoogle Scholar
• 49 Mwinga A, Hosp M, Godfrey-Faussett P et al.. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia.  AIDS. 1998;  12 2447-2457
  CrossrefPubMedGoogle Scholar
• 50 Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.  Lancet. 1999;  353 1843-1847
  CrossrefPubMedGoogle Scholar
• 51 Pepper T, Joseph P, Mwenya C et al.. Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory specimen cultures.  Int J Tuberc Lung Dis. 2008;  12 397-403
  PubMedGoogle Scholar
• 52 Shafer R W, Edlin B R. Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade.  Clin Infect Dis. 1996;  22 683-704
  PubMedGoogle Scholar
• 53 Hong Kong Chest Service/British Medical Research Council . A double-blind placebo controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong.  Am Rev Respir Dis. 1992;  145 36-41
  PubMedGoogle Scholar
• 54 Polesky A, Farber H W, Gottlieb D J et al.. Rifampin preventive therapy for tuberculosis in Boston's homeless.  Am J Respir Crit Care Med. 1996;  154 1473-1477
  CrossrefPubMedGoogle Scholar
• 55 Villarino M E, Ridzon R, Weismuller P C et al.. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents.  Am J Respir Crit Care Med. 1997;  155 1735-1738
  CrossrefPubMedGoogle Scholar
• 56 Menzies D, Dion M J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.  Am J Respir Crit Care Med. 2004;  170 445-449
  CrossrefPubMedGoogle Scholar
• 57 Page K R, Sifakis F, Montes de Oca R et al.. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.  Arch Intern Med. 2006;  166 1863-1870
  CrossrefPubMedGoogle Scholar
• 58 Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman L B. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.  Chest. 2006;  130 1712-1717
  CrossrefPubMedGoogle Scholar
• 59 Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.  Clin Infect Dis. 2005;  40 670-676
  CrossrefPubMedGoogle Scholar
• 60 Spyridis N P, Spyridis P G, Gelesme A et al.. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.  Clin Infect Dis. 2007;  45 715-722
  CrossrefPubMedGoogle Scholar
• 61 Rennie T W, Bothamley G H, Engova D, Bates I P. Patient choice promotes adherence in preventive treatment for latent tuberculosis.  Eur Respir J. 2007;  30 728-735
  CrossrefPubMedGoogle Scholar
• 62 Ormerod L P. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis.  Arch Dis Child. 1998;  78 169-171
  CrossrefPubMedGoogle Scholar
• 63 Steele M A, Burk R F, DesPrez R M. Toxic hepatitis with isoniazid and rifampin: a meta-analysis.  Chest. 1991;  99 465-471
  CrossrefPubMedGoogle Scholar
• 64 Schechter M, Zajdenverg R, Falco G et al.. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.  Am J Respir Crit Care Med. 2006;  173 922-926
  CrossrefPubMedGoogle Scholar
• 65 Churchyard G J, Scano F, Grant A D, Chaisson R E. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities.  J Infect Dis. 2007;  196(Suppl 1) S52-S62
  CrossrefPubMedGoogle Scholar
• 66 Centers for Disease Control and Prevention (CDC): American Thoracic Society . Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection–United States, 2003.  MMWR Morb Mortal Wkly Rep. 2003;  52 735-739
  PubMedGoogle Scholar
• 67 Gordin F, Chaisson R E, Matts J P et al.. Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in HIV-infected persons. An international randomized trial.  JAMA. 2000;  283 1445-1450
  CrossrefPubMedGoogle Scholar
• 68 Halsey N A, Coberly J, Desormeaux J et al.. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.  Lancet. 1998;  351 786-792
  CrossrefPubMedGoogle Scholar
• 69 Bock N N, Rogers T, Tapia J R, Herron G D, DeVoe B, Geiter L J. Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates.  Chest. 2001;  119 833-837
  CrossrefPubMedGoogle Scholar
• 70 Chaisson R E, Armstrong J, Stafford J, Golub J, Bur S. Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners.  JAMA. 2002;  288 165-166
  CrossrefPubMedGoogle Scholar
• 71 Jasmer R M, Saukkonen J J, Blumberg H M et al.. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.  Ann Intern Med. 2002;  137 640-647
  CrossrefPubMedGoogle Scholar
• 72 Lee A M, Mennone J Z, Jones R C, Paul W S. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.  Int J Tuberc Lung Dis. 2002;  6 995-1000
  PubMedGoogle Scholar
• 73 McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.  Chest. 2003;  123 102-106
  CrossrefPubMedGoogle Scholar
• 74 Stout J E, Engemann J J, Cheng A C, Fortenberry E R, Hamilton C D. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.  Am J Respir Crit Care Med. 2003;  167 824-827
  CrossrefPubMedGoogle Scholar
• 75 van Hest R, Baars H, Kik S et al.. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.  Clin Infect Dis. 2004;  39 488-496
  CrossrefPubMedGoogle Scholar
• 76 Cook P P, Maldonado R A, Yarnell C T, Holbert D. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.  Clin Infect Dis. 2006;  43 271-275
  CrossrefPubMedGoogle Scholar
• 77 Lobato M N, Reves R R, Jasmer R M, Grabau J C, Bock N N, Shang N. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons.  Chest. 2005;  127 1296-1303
  CrossrefPubMedGoogle Scholar
• 78 Gordin F M, Cohn D L, Matts J P, Chaisson R E, O'Brien R J. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?.  Clin Infect Dis. 2004;  39 561-565
  CrossrefPubMedGoogle Scholar
• 79 Narita M, Kellman M, Franchini D L, McMillan M E, Hollender E S, Ashkin D. Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida.  Chest. 2002;  122 1292-1298
  CrossrefPubMedGoogle Scholar
• 80 McElroy P D, Ijaz K, Lambert L A et al.. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.  Clin Infect Dis. 2005;  41 1125-1133
  CrossrefPubMedGoogle Scholar
• 81 Ijaz K, Jereb J A, Lambert L A et al.. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection.  Clin Infect Dis. 2006;  42 346-355
  CrossrefPubMedGoogle Scholar
• 82 Fraser A, Paul M, Attamna A, Leibovici L. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review.  Int J Tuberc Lung Dis. 2006;  10 19-23
  PubMedGoogle Scholar
• 83 Schaaf H S, Vermeulen H A, Gie R P, Beyers N, Donald P R. Evaluation of young children in household contact with adult multidrug-resistant pulmonary tuberculosis cases.  Pediatr Infect Dis J. 1999;  18 494-500
  CrossrefPubMedGoogle Scholar
• 84 Management of persons exposed to multidrug-resistant tuberculosis.  MMWR Recomm Rep. 1992;  41(RR-11) 61-71
  PubMedGoogle Scholar
• 85 Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato I M. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin.  Clin Infect Dis. 1997;  24 1264-1265
  PubMedGoogle Scholar
• 86 Nuermberger E L, Yoshimatsu T, Tyagi S et al.. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.  Am J Respir Crit Care Med. 2004;  169 421-426
  PubMedGoogle Scholar
• 87 Nuermberger E L, Yoshimatsu T, Tyagi S et al.. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.  Am J Respir Crit Care Med. 2004;  170 1131-1134
  CrossrefPubMedGoogle Scholar
• 88 Nuermberger E, Tyagi S, Williams K N, Rosenthal I, Bishai W R, Grosset J H. Rifapentine, moxifloxacin or DNA vaccine improves treatment of latent tuberculosis in a mouse model.  Am J Respir Crit Care Med. 2005;  172 1452-1456
  CrossrefPubMedGoogle Scholar
• 89 Spigelman M K. New tuberculosis therapeutics: a growing pipeline.  J Infect Dis. 2007;  196(Suppl 1) S28-S34
  CrossrefPubMedGoogle Scholar

Timothy R SterlingM.D. 

Division of Infectious Diseases, Vanderbilt University School of Medicine

A2209 Medical Center North, 1161 21st Ave. South, Nashville, TN 37232

Email: timothy.sterling@vanderbilt.edu